Shares of MoonLake Immunotherapeutics (MLTX) rose 1% in after-hours trading, closing at $18, following the presentation of encouraging data for Sonelokimab at the EULAR conference in London. H.C. Wainwright reaffirmed its 'Buy' rating and set a price target of $45, indicating a 150% upside from current levels. In a study involving patients with axial spondyloarthritis, 77% experienced symptom improvements after just two doses of Sonelokimab, with over half achieving partial remission by week 12. Additionally, MoonLake successfully concluded its final FDA pre-BLA meeting for Sonelokimab in hidradenitis suppurativa, aligning on submission plans and safety data requirements. The company aims to file its BLA by the end of September, with results from the Mira trial showing 43% of patients achieving significant disease improvement. Investors are eagerly awaiting further clinical data, including results from multiple Phase 3 trials expected later this year, which could significantly impact MLTX's stock performance. Retail sentiment remains highly positive, with a notable increase in message activity on Stocktwits.